Leish-111f + MPL-SE Vaccine(IDRI)(Leish-111f + MPL-SE Vaccine(IDRI))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域-

在研适应症-

非在研适应症-

原研机构

Infectious Disease Research Institute

在研机构-

非在研机构-

权益机构-

最高研发阶段-

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

1

项与 Leish-111f + MPL-SE Vaccine(IDRI) 相关的临床试验

NCT00486382

/ Completed临床1期IIT

A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India

The purpose of this study is to determine if a vaccine (called Leish-111f + MPL-SE) is safe and whether it can or cannot produce a protective response against visceral leishmaniasis when injected to healthy subjects.

开始日期2007-04-01

申办/合作机构